BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
Tag: hematologic malignancies
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
CAR T Cell Therapy: The Truth About Off-the-Shelf Treatments in 2026
CAR T Cell Therapy The Truth About Off-the-Shelf Treatments in 2026 Review Key Takeaways Chimeric antigen receptor T cell therapy has transformed the treatment landscape for several hematologic malignancies, offering the potential for durable remission in patients with otherwise refractory disease. Conventional CAR T cell therapy relies on
